Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study

Basit Öğe Kaydı
dc.contributor.authorRojas, Carlos
dc.contributor.authorEskens, Ferry
dc.contributor.authorGhiringhelli, Francois
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorCaglevic, Christian
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorTosi, Diego
dc.date.accessioned2025-05-10T19:27:41Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionSpecial Clinical Science Symposia -- MAY 29-29, 2024 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7034
dc.identifier.volume42
dc.identifier.wosWOS:001275557401352
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleVibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu